Various Applications of Tofacitinib and Ruxolitinib (Janus Kinase Inhibitors) in Dermatology and Rheumatology: A Review of Current Evidence and Future Perspective
Backgrounds: Janus kinase inhibitors (JAKi) are anti-inflammatory medications suppressing Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway by inhibiting various cytokines receptors on the membrane of cells. Mutations and polymorphisms on JAK and STAT proteins can caus...
Saved in:
Main Authors: | Sara Sadeghi (Author), Azadeh Goodarzi (Author) |
---|---|
Format: | Book |
Published: |
Mattioli1885,
2022-10-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Janus kinase inhibitors - their current applications and future prospects
by: Natalia Wierzbowska, et al.
Published: (2022) -
Topical Tofacitinib: A Janus Kinase Inhibitor for the Treatment of Vitiligo in an Adolescent Patient
by: Sineida Berbert Ferreira, et al.
Published: (2021) -
Antipruritic Effects of Janus Kinase Inhibitor Tofacitinib in a Mouse Model of Psoriasis
by: Takashi Hashimoto, et al.
Published: (2019) -
Janus Kinase inhibitors in dermatology: a review
by: Bárbara Vieira-Granja, et al.
Published: (2023) -
A case of aggressive squamous cell carcinoma with lymphovascular invasion during treatment with the Janus kinase inhibitor tofacitinib
by: Ahmad I. Aleisa, MD, et al.
Published: (2020)